Sevoflurane Sedation in Patients With Septic Shock
ConditionShock, Septic
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorUniversity of Zurich
About this trial
Recent in vivo studies from others as well as the investigators group demonstrated that volatile anesthetics immunomodulate sepsis and improve outcome. Also, several clinical trials have convincingly shown that application of a volatile anesthetic provides protection in patients undergoing major surgery.
Patients with sepsis are intubated and ventilated and therefore need sedation. So far, most ICU centers use intravenously applied sedatives in these patients. In the proposed study, we will switch sedation from an intravenous to a volatile anesthetic for a short period of time to explore if sepsis markers improve within the following 120 hours upon sevoflurane conditioning.
Eligibility criteria
Qualifiers
Male and female patients, age 18 to 80 years
Intensive care Unit (ICU) patients with septic shock (despite fluid resuscitation vasopressors needed to maintain mean arterial pressure ≥65 millimeter of mercury (mmHg), and serum lactate >2mmol/l even with fluid application)
Treatment of septic shock on ICU with vasopressors not longer than 12 hours
Sedation and mechanical ventilation on ICU
Disqualifiers
Previous surgery and/or anesthesia (within last 7 days)
Application of nitric oxide (NO)
Suspected or known intolerance by history to volatile anesthetics (malignant hyperthermia)
Immunosuppressive agents
Trial design
Treatments tested in this trial
- Sevoflurane
- Control Group
Treatment groups
153 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Zurich
Lead sponsor
Kantonsspital Münsterlingen
Collaborator
Triemli Hospital
Collaborator
Waid City Hospital, Zurich
Collaborator
Source ClinicalTrials.gov